NASDAQ:TYME

Tyme Technologies Competitors

$1.53
+0.01 (+0.66 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.42
Now: $1.53
$1.55
50-Day Range
$1.52
MA: $1.88
$2.27
52-Week Range
$0.85
Now: $1.53
$4.99
Volume2.03 million shs
Average Volume10.14 million shs
Market Capitalization$199.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94

Competitors

Tyme Technologies (NASDAQ:TYME) Vs. HGEN, ORIC, ESPR, LXRX, KPTI, and ZIOP

Should you be buying TYME stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Tyme Technologies, including Humanigen (HGEN), ORIC Pharmaceuticals (ORIC), Esperion Therapeutics (ESPR), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), and ZIOPHARM Oncology (ZIOP).

Humanigen (NASDAQ:HGEN) and Tyme Technologies (NASDAQ:TYME) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Humanigen and Tyme Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
Tyme TechnologiesN/A-192.69%-111.68%

Volatility & Risk

Humanigen has a beta of -0.79, suggesting that its stock price is 179% less volatile than the S&P 500. Comparatively, Tyme Technologies has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Humanigen and Tyme Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
Tyme TechnologiesN/AN/A$-22,000,000.00($0.17)-9.00

Insider and Institutional Ownership

30.2% of Humanigen shares are held by institutional investors. Comparatively, 13.0% of Tyme Technologies shares are held by institutional investors. 37.5% of Humanigen shares are held by insiders. Comparatively, 25.5% of Tyme Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Humanigen and Tyme Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
Tyme Technologies00203.00

Humanigen currently has a consensus price target of $29.8333, indicating a potential upside of 102.53%. Tyme Technologies has a consensus price target of $9.50, indicating a potential upside of 520.92%. Given Tyme Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Tyme Technologies is more favorable than Humanigen.

Summary

Tyme Technologies beats Humanigen on 5 of the 9 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Tyme Technologies (NASDAQ:TYME) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares ORIC Pharmaceuticals and Tyme Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
Tyme TechnologiesN/AN/A$-22,000,000.00($0.17)-9.00

Profitability

This table compares ORIC Pharmaceuticals and Tyme Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
Tyme TechnologiesN/A-192.69%-111.68%

Analyst Ratings

This is a summary of current ratings for ORIC Pharmaceuticals and Tyme Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
Tyme Technologies00203.00

ORIC Pharmaceuticals presently has a consensus price target of $43.7143, indicating a potential upside of 104.94%. Tyme Technologies has a consensus price target of $9.50, indicating a potential upside of 520.92%. Given Tyme Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Tyme Technologies is more favorable than ORIC Pharmaceuticals.

Insider & Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.0% of Tyme Technologies shares are owned by institutional investors. 25.5% of Tyme Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ORIC Pharmaceuticals beats Tyme Technologies on 4 of the 7 factors compared between the two stocks.

Tyme Technologies (NASDAQ:TYME) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Tyme Technologies and Esperion Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyme TechnologiesN/AN/A$-22,000,000.00($0.17)-9.00
Esperion Therapeutics$148.36 million5.09$-97,170,000.00($3.59)-7.53

Tyme Technologies has higher earnings, but lower revenue than Esperion Therapeutics. Tyme Technologies is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tyme Technologies and Esperion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tyme TechnologiesN/A-192.69%-111.68%
Esperion Therapeutics-46.15%-629.88%-41.43%

Volatility & Risk

Tyme Technologies has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tyme Technologies and Esperion Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tyme Technologies00203.00
Esperion Therapeutics24312.30

Tyme Technologies presently has a consensus target price of $9.50, indicating a potential upside of 520.92%. Esperion Therapeutics has a consensus target price of $50.60, indicating a potential upside of 87.27%. Given Tyme Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Tyme Technologies is more favorable than Esperion Therapeutics.

Insider & Institutional Ownership

13.0% of Tyme Technologies shares are owned by institutional investors. 25.5% of Tyme Technologies shares are owned by company insiders. Comparatively, 7.7% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tyme Technologies beats Esperion Therapeutics on 9 of the 14 factors compared between the two stocks.

Tyme Technologies (NASDAQ:TYME) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Tyme Technologies and Lexicon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyme TechnologiesN/AN/A$-22,000,000.00($0.17)-9.00
Lexicon Pharmaceuticals$322.07 million2.26$130.13 million$1.353.74

Lexicon Pharmaceuticals has higher revenue and earnings than Tyme Technologies. Tyme Technologies is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tyme Technologies and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tyme TechnologiesN/A-192.69%-111.68%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Volatility & Risk

Tyme Technologies has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tyme Technologies and Lexicon Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tyme Technologies00203.00
Lexicon Pharmaceuticals06202.25

Tyme Technologies presently has a consensus target price of $9.50, indicating a potential upside of 520.92%. Lexicon Pharmaceuticals has a consensus target price of $9.40, indicating a potential upside of 86.14%. Given Tyme Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Tyme Technologies is more favorable than Lexicon Pharmaceuticals.

Insider & Institutional Ownership

13.0% of Tyme Technologies shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 25.5% of Tyme Technologies shares are owned by company insiders. Comparatively, 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Lexicon Pharmaceuticals beats Tyme Technologies on 8 of the 12 factors compared between the two stocks.

Tyme Technologies (NASDAQ:TYME) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Tyme Technologies and Karyopharm Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyme TechnologiesN/AN/A$-22,000,000.00($0.17)-9.00
Karyopharm Therapeutics$40.89 million17.82$-199,590,000.00($3.22)-3.02

Tyme Technologies has higher earnings, but lower revenue than Karyopharm Therapeutics. Tyme Technologies is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tyme Technologies and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tyme TechnologiesN/A-192.69%-111.68%
Karyopharm Therapeutics-221.23%-187.66%-56.42%

Volatility & Risk

Tyme Technologies has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tyme Technologies and Karyopharm Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tyme Technologies00203.00
Karyopharm Therapeutics01802.89

Tyme Technologies presently has a consensus target price of $9.50, indicating a potential upside of 520.92%. Karyopharm Therapeutics has a consensus target price of $29.8750, indicating a potential upside of 207.67%. Given Tyme Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Tyme Technologies is more favorable than Karyopharm Therapeutics.

Insider & Institutional Ownership

13.0% of Tyme Technologies shares are owned by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are owned by institutional investors. 25.5% of Tyme Technologies shares are owned by company insiders. Comparatively, 13.3% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tyme Technologies beats Karyopharm Therapeutics on 7 of the 13 factors compared between the two stocks.

Tyme Technologies (NASDAQ:TYME) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Tyme Technologies and ZIOPHARM Oncology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyme TechnologiesN/AN/A$-22,000,000.00($0.17)-9.00
ZIOPHARM Oncology$150,000.004,777.55$-117,800,000.00($0.34)-9.79

Tyme Technologies has higher earnings, but lower revenue than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Tyme Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tyme Technologies and ZIOPHARM Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tyme TechnologiesN/A-192.69%-111.68%
ZIOPHARM OncologyN/A-48.49%-43.53%

Volatility & Risk

Tyme Technologies has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tyme Technologies and ZIOPHARM Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tyme Technologies00203.00
ZIOPHARM Oncology03202.40

Tyme Technologies presently has a consensus target price of $9.50, indicating a potential upside of 520.92%. ZIOPHARM Oncology has a consensus target price of $5.90, indicating a potential upside of 77.18%. Given Tyme Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Tyme Technologies is more favorable than ZIOPHARM Oncology.

Insider & Institutional Ownership

13.0% of Tyme Technologies shares are owned by institutional investors. Comparatively, 48.0% of ZIOPHARM Oncology shares are owned by institutional investors. 25.5% of Tyme Technologies shares are owned by company insiders. Comparatively, 2.3% of ZIOPHARM Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ZIOPHARM Oncology beats Tyme Technologies on 6 of the 11 factors compared between the two stocks.


Tyme Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Humanigen logo
HGEN
Humanigen
1.7$14.73+5.6%$787.79 millionN/A0.00Increase in Short Interest
Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.33+2.7%$782.70 millionN/A0.00Increase in Short Interest
Gap Down
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.02+0.1%$755.02 million$148.36 million-7.02Analyst Revision
News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05+3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.71+0.2%$728.84 million$40.89 million-3.35
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33+2.7%$716.63 million$150,000.00-4.76
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.63+1.9%$702.93 million$6.83 million-20.24
Chimerix logo
CMRX
Chimerix
1.3$8.18+1.6%$700.85 million$12.52 million-14.35Analyst Upgrade
Increase in Short Interest
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.71+7.0%$688.35 million$2.22 million-15.94Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.45+1.8%$680 million$13.80 million-14.23
Veru logo
VERU
Veru
1.4$9.42+1.8%$677.41 million$42.59 million-33.64Analyst Report
Analyst Revision
News Coverage
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.90+4.2%$673.79 million$17.26 million-4.42Analyst Revision
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.92+0.5%$673.52 million$5.09 million-6.53Analyst Downgrade
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.88+1.2%$671.22 million$19.56 million-19.34News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28+1.3%$669.56 million$252 million-2.07
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.49+4.2%$641.23 millionN/A-2.38Analyst Downgrade
Increase in Short Interest
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98+2.0%$625.09 million$143.01 million-1.14
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.60+1.0%$623.12 million$9.64 million-5.31
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.56+0.0%$616.55 millionN/A-4.64Analyst Revision
News Coverage
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58+5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.61+0.5%$600.36 millionN/A-9.90Analyst Report
High Trading Volume
News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.72+1.6%$594.39 million$8 million-8.01News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.45+3.1%$594.33 million$12.69 million-11.75Increase in Short Interest
Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$2.52+1.6%$585.32 million$64.61 million-3.71Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$44.27+0.1%$585.12 million$195.89 million126.49News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.69+4.9%$580.95 millionN/A-16.06
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.44+0.7%$560.95 millionN/A-5.36
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.26+1.5%$557.19 million$26.74 million18.15
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.73+3.5%$552.58 million$1.19 million-6.97
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.95+3.7%$536.51 millionN/A-4.72
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.00+1.5%$534.12 millionN/A-5.64Analyst Upgrade
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.28+2.6%$532.95 millionN/A-8.74Increase in Short Interest
News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.87+1.4%$518.95 millionN/A-8.22Unusual Options Activity
News Coverage
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.11+1.8%$516.12 millionN/A-4.07
Inventiva logo
IVA
Inventiva
0.0$13.34+0.5%$515.32 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$8.11+0.4%$513.97 millionN/A-5.44Analyst Report
Increase in Short Interest
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.96+2.0%$506.22 million$25 million-18.40
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.62+0.8%$503.97 million$59.22 million43.10
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$36.80+0.1%$497.13 million$40,000.00-1.60Upcoming Earnings
XBiotech logo
XBIT
XBiotech
1.0$16.81+2.3%$495.21 millionN/A1.16
89bio logo
ETNB
89bio
1.6$24.77+2.5%$494.06 millionN/A-4.90
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.75+1.7%$493.31 million$58.12 million-15.99Decrease in Short Interest
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.51+1.9%$486.53 million$57.49 million-6.31Increase in Short Interest
News Coverage
Gap Down
AC Immune logo
ACIU
AC Immune
1.3$6.73+4.9%$484.14 million$111.75 million-7.48
Evolus logo
EOLS
Evolus
1.5$10.97+2.7%$479.75 million$34.92 million-5.40Analyst Report
Gap Down
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.19+1.7%$478.45 million$49.65 million-1.68Analyst Upgrade
Akouos logo
AKUS
Akouos
1.6$13.76+12.8%$473.37 millionN/A0.00Gap Down
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.41+2.8%$469.79 million$72.96 million-3.05Analyst Report
Analyst Revision
News Coverage
Geron logo
GERN
Geron
1.4$1.47+2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.